Optoacoustic sensors for early disease detection and monitoring

Información del proyecto

RSENSE4Health

Identificador del acuerdo de subvención: 101034883

DOI

10.3030/101034883

Proyecto cerrado

Fecha de la firma de la CE 16 Marzo 2021

Fecha de inicio 1 Septiembre 2021

Fecha de finalización 31 Mayo 2023

Financiado con arreglo a

• EXCELLENT SCIENCE - Future and Emerging Technologies (FET)

Coste total

Sin datos

Aportación de la UE

€ 100 000,00

Coordinado por

TECHNISCHE UNIVERSITAET MUENCHEN
Germany

Periodic Reporting for period 1 - RSENSE4Health (Optoacoustic sensors for early disease detection and monitoring)

Período documentado: 2021-09-01 hasta 2023-05-31

Resumen del contexto y de los objetivos generales del proyecto

Diabetes and cardiovascular disease (CVD) are responsible for the majority of the morbidity and mortality in the EU. However, to date there is no technology available that offers a non-invasive and portable way for disseminated measurements of disease effects on the systemic level or for monitoring disease progression from early development stages. RSENSE4Health aims to accelerate the exploitation of a powerful, portable optoacoustic sensor, developed under the RSENSE project, an EU project funded under the FET programme. For the first time, this sensor can non-invasively detect the systemic effects of diabetes and CVD developing in home environments – a performance not available to any other sensors. With more than one billion potential users, this technology has an enormous market and global impact potential. To bring this innovation to the market, RSENSE4Health will sharpen product specifications with stakeholder interviews, solidify patent strategy, and identify an optimal regulatory and business roadmap in order to accelerate company spin-off and product launch.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

A market analysis was performed to define product specifications for market deployment; develop an implementation roadmap; and identify regulatory barriers and requirements. The work carried out on RSENSE4Health was based on the optoacoustic medical sensor developed through RSENSE Project (GA #862811). We have successfully identified pathways towards a health insurance reimbursement and confirmed interest by key opinion leaders and other relevant stakeholders in our product. A market entry strategy was developed.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

RSENSE4Health promises to drive healthcare transition by providing so far inaccessible diagnostic biomarkers, e.g. microvessel parameters linked to diabetes and CVD. For the first time, this performance can enable remote diagnostics and therapy monitoring of these diseases, beyond the wellness use of current wearables.
When the sensor is ready and launched, we foresee the following socio-economic impacts:
- Our innovation will contribute to strengthen the position of the EU as global market leader in healthcare provision and MedTech development maintaining independence from other technologies and countries
- Ease the burden of disease of diabetes and CVD
- Longitudinal Precision Medicine and personalised therapy
- Reduce healthcare costs
- Improve healthcare access

RSENSE4Health logo